昆药集团: 昆药集团十一届五次董事会决议公告

Group 1 - The board of directors of Kunming Pharmaceutical Group Co., Ltd. held its fifth meeting of the 11th session on May 29, 2025, and approved the decision to apply for the cancellation of its wholly-owned subsidiary, Kunming Shenghuo Pharmaceutical Co., Ltd., due to its lack of actual business operations [1] - The board approved the acquisition of exclusive commercialization rights for the drug JL2401 for 12 million RMB and allocated 29.2 million RMB for subsequent research and development activities and drug listing application, totaling 41.2 million RMB [1] - All resolutions were passed unanimously with 9 votes in favor, 0 against, and 0 abstentions [2]